title: [89Zr]Trastuzumab: Evaluation of Radiation Dosimetry, Safety, and Optimal Imaging Parameters in Women with HER2-Positive Breast Cancer.
abstract: The purpose of the present study is to evaluate safety, human radiation dosimetry, and optimal imaging time of [89Zr]trastuzumab in patients with HER2-positive breast cancer.
  
  
  
  Twelve women with HER2-positive breast cancer underwent [89Zr]trastuzumab positron emission tomography (PET)/X-ray computed tomography (CT) twice within 7 days post-injection. Biodistribution data from whole-torso PET/CT images and organ time-activity curves were created using data from all patients. Human dosimetry was calculated using OLINDA with the adult female model.
  
  
  
  High-quality images and the greatest tumor-to-nontumor contrast were achieved with images performed 5 ± 1 day post-injection. Increased [89Zr]trastuzumab uptake was seen in at least one known lesion in ten patients. The liver was the dose-limiting organ (retention of ∼12 % of the injected dose and average dose of 1.54 mSv/MBq). The effective dose was 0.47 mSv/MBq. No adverse effects of [89Zr]trastuzumab were encountered.
  
  
  
  [89Zr]trastuzumab was safe and optimally imaged at least 4 days post-injection. The liver was the dose-limiting organ.
authors.affiliation: Division of Radiological Sciences, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, USA. laforestr@wustl.edu.|The Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA. laforestr@wustl.edu.
authors.forename: Richard
authors.initials: R
authors.lastname: Laforest
authors.affiliation: Division of Radiological Sciences, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, USA.|The Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA.
authors.forename: Suzanne E
authors.initials: SE
authors.lastname: Lapi
authors.affiliation: Division of Radiological Sciences, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, USA.
authors.forename: Reiko
authors.initials: R
authors.lastname: Oyama
authors.affiliation: The Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA.|Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
authors.forename: Ron
authors.initials: R
authors.lastname: Bose
authors.affiliation: Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
authors.forename: Adel
authors.initials: A
authors.lastname: Tabchy
authors.affiliation: Division of Radiological Sciences, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, USA.
authors.forename: Bernadette V
authors.initials: BV
authors.lastname: Marquez-Nostra
authors.affiliation: Division of Radiological Sciences, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, USA.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Burkemper
authors.affiliation: Division of Radiological Sciences, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, USA.
authors.forename: Brian D
authors.initials: BD
authors.lastname: Wright
authors.affiliation: Division of Nuclear Medicine, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, USA.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Frye
authors.affiliation: Division of Nuclear Medicine, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, USA.
authors.forename: Sarah
authors.initials: S
authors.lastname: Frye
authors.affiliation: The Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA.|Division of Nuclear Medicine, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, USA.
authors.forename: Barry A
authors.initials: BA
authors.lastname: Siegel
authors.affiliation: The Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA.|Division of Nuclear Medicine, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO, USA.
authors.forename: Farrokh
authors.initials: F
authors.lastname: Dehdashti
mesh_terms: D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology; D005260:Female; D006801:Humans; D008875:Middle Aged; D000072078:Positron Emission Tomography Computed Tomography; D011868:Radioisotopes / Q000737:chemistry*; D011874:Radiometry; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D013997:Time Factors; D014018:Tissue Distribution; D000068878:Trastuzumab / Q000009:adverse effects / Q000627:therapeutic use*; D015040:Zirconium / Q000737:chemistry*
chemical_list: D011868:Radioisotopes; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; D015040:Zirconium
keywords: Dosimetry; HER2; PET imaging; Trastuzumab; Zirconium-89